[ACCESSWIRE]
LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance sheets, revenues, earnings and earnings per share. When investing in biotech throw that out the window.
In biotech, patents and intellectual property rights are like revenues and earnings in any other industry or sector, progress is measured by clinical trials and their results. With that in mind, let's look at a few biotechnology companies that are experiencing exponential growth.
Propanc Health Group (PPCH) a cancer stem cell company has made incredible strides in the past year.
PPCH has been working since 2007 at creating their PRP cancer treatment. The past year has seen the company grow exponentially. Their PRP treatment focuses on attacking metastasis which is essentially the spread of cancer cells, one of the largest problems facing oncology.
Let's look at some of the past year's major highlights:
- To date the company has filed 3 patents for the use of PRP, one of which includes a method treating cancer by targeting cancer stem cell eradication, whilst sparing normal stem cells.
- Over the past year the company has gone through several animal trials, receiving positive results moving closer to human trials.
- For investors, PPCH, began a major debt reduction initiative and reduced its authorized shares by 80%!
- Traders saw a 13,000% move in PPCH which has made the company very popular among investors.
- The company retained Maxim Group LLC. to help the company up list to a major national exchange; so far the company up listed to the OTCQB and then was chosen for the exclusive OTCQB Venture Index, which is considered a benchmark for the OTC market's performance.
- Recently announced their intention to develop new compounds in a strategic collaboration with their research partners at the Universities of Granada and Jaèn, Spain, as well as the Foundation for Bio-Health Research Oriental, Andalucia, Spain, based on the mechanism of action of PRP.
- PPCH has had success with their animal studies, and commenced animal toxicology studies to determine the proper dosage for Phase 1 Human Trials
- The company announced its plans to seek Orphan Drug Designation which would significantly lower the costs of dealing with regulatory agencies for a 7 to 10 year period.
- Possibly most importantly the company secured $4 million in financing, which will help get the company to human trials, of which they've only drawn $2.4 million, leaving $1.6 million in additional funding for the company.
This has been a truly AMAZING year for the company. As we head deeper into 2016 there's still a ton of progress PPCH is poised to make and investors should pay close attention. One development that could be particularly impactful is a recent BBC report which you can watch here: http://www.bbc.com/news/health-35585571. The report, discussed a study and trial of immunotherapy which has been highly successful and could prompt a cancer treatment 'revolution'. PPCH's PRP treatment is considered complementary to immunotherapy, by targeting chemo-resistant cancer stem cells which often remain undetected by the body's immune system.
Second Sight Medical Products, Inc. (EYES) is another biotech company making enormous strides. Their mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. This type of technology is the stuff of science fiction, but EYES is turning it into science fact.
EYES's technology is not for all blind people, but for the individuals who lost their vision due to retinitis pigmentosa (RP) which severely damages the photoreceptors in our eyes. Second Sight has already developed and has started manufacturing the Argus® II Retinal Prosthesis System.
Geron Corporation (GERN) has put all of its weight behind developing a single drug following its restructuring process that started in 2011. This drug is a telomerase inhibitor called imetelstat that has the potential to be a truly disease-modifying treatment for deadly blood disorders such as myelofibrosis and myelodysplastic syndrome. Despite some rough financial reports recently continues to earn investors as it fights to reward them for taking the risk.
Advaxis, Inc. (ADXS), a clinical stage biotechnology company developing cancer immunotherapies, president and CEO Daniel J. O'Connor, presented an overview of the company's business strategy and corporate programs at the 2016 RBC Capital Markets Global Healthcare Conference at the New York Palace in New York City. After a slight dip on the presentation, the company is recovering making gains for investors so far in March.
Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company that focuses on therapies for Alzheimer's Disease, has encouraged investors with the company's preclinical results of its ANAVEX 2-73 in an exploratory study in a Rett syndrome model.
"The data demonstrates dose related and significant improvements in an array of behavioral and gait paradigms in a mouse model with a MECP2-null mutation that causes neurological symptoms that mimic Rett syndrome. There is a tremendous need for therapeutic solutions for the individuals living with Rett syndrome and their families, and we are very encouraged by the data we have seen with ANAVEX 2-73," said Steven Kaminsky, PhD, Chief Science Officer of Rettsyndrome.org.
Stemline Therapeutics, Inc. (STML), a clinical stage biopharmaceutical company developing novel oncology therapeutics, had their CEO Ivan Bergstein, M.D., present at the BIO CEO & Investor Conference VSTM presented at. After announcing their progress over the past year, the company has erased a bearish move heading into the presentation.
ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC) announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell receptors (TCRs) developed in the laboratory of Prof. Mark Davis, Director, Stanford Institute for Immunity, Transplantation and Infection, and The Burt and Marion Avery Family Professor of Immunology at Stanford University School of Medicine. This news has been received favorably by investors sending the stock from 24 cents a share to a high of 32.
As noted investing in biotechnology is a different beast than other markets, however, there's one major indicator that always benefits investors and that's tangible progress. PPCH's progress over the past 12 months has been simply exceptional, and we are an announcement or two away from another major run for the stock similar to the 13,000% move it made earlier this year. Investors should pay close attention.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com
Contact:
SOURCE: ACR Communication, LLC